as on October 24, 2025 at 10:27 pm IST
Day's High
5.08%
Upside
52 Week's Low
52 Week's High
11.83%
Downside
442.37%
Upside
Check Virax Biolabs Group Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$2.6M
EPS (TTM)
-1.48
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
-114.47%
Compare market cap, revenue, PE, and other key metrics of Virax Biolabs Group Ltd with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| NA | $2.6M | NA | NA | 0.00% | |
| BUY | $60.9B | 251.94% | -505.15 | -12.96% | |
| NA | $35.9B | NA | NA | -3.89% | |
| BUY | $109.3B | 99.75% | 30.31 | 31.86% | |
| BUY | $62.0B | -0.71% | 14.73 | 31.37% |
The Virax Biolabs Group Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Virax Biolabs Group Ltd investment value today
Current value as on today
₹27,519
Returns
Returns from Virax Biolabs Group Ltd Stock
Dollar Returns*
₹4,562 (+4.56%)
Search interest for Virax Biolabs Group Ltd Stock has decreased by -7% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.0% return, outperforming this stock by 135.0%
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 136.9% return, outperforming this stock by 232.6%
Profit Down
![]()
Netprofit is down for the last 2 quarters, -2.75M → -3.30M (in $), with an average decrease of 19.9% per quarter
Price Dip
![]()
In the last 3 months, VRAX stock has moved down by -42.7%
Revenue Fall
![]()
Revenue is down for the last 3 quarters, 79.91K → 1.37K (in $), with an average decrease of 83.0% per quarter
| Organisation | Virax Biolabs Group Ltd |
| Headquarters | BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH |
| CEO | Mr. James Foster |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Ms. Lily Fu | Head of Supply Chain |
Mr. James Foster | Chairman, CEO & Principal Accounting Officer |
Dr. Nigel McCracken M.Sc., Ph.D. | COO & Director |
Mr. Clement Monteil | Head of Scientific Research & Development |
Virax Biolabs Group Ltd share price today is $0.59 as on . Virax Biolabs Group Ltd share today touched a day high of $0.62 and a low of $0.59.
Virax Biolabs Group Ltd share touched a 52 week high of $3.2 on and a 52 week low of $0.52 on . Virax Biolabs Group Ltd stock price today i.e. is trending at $0.59,which is 81.56% down from its 52 week high and 13.42% up from its 52 week low.
Virax Biolabs Group Ltd market capitalisation is $0.00T as on .
Indian investors can start investing in Virax Biolabs Group Ltd (VRAX) shares with as little as ₹87.759 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹877.59 in Virax Biolabs Group Ltd stock (as per the Rupee-Dollar exchange rate as on ).
Based on Virax Biolabs Group Ltd share’s latest price of $0.59 as on October 24, 2025 at 10:27 pm IST, you will get 16.9492 shares of Virax Biolabs Group Ltd. Learn more about
fractional shares .